ITGA6 rs16860513: Understanding Prostate Cancer Risk Markers
The rs16860513 variant is a common genetic marker located within the ITGA6 gene. It has been identified in research studies as a potential factor for prostate cancer risk stratification.
What each genotype means
Typical risk profile
This genotype represents the most common genetic state for this location in the ITGA6 gene. Research into this specific variant suggests it serves as a marker for prostate cancer risk stratification, though the clinical impact of this specific genotype is considered moderate. It is not a diagnostic indicator, and you should discuss any concerns regarding prostate health with your physician.
This is the most common genotype observed in most global populations.
Potential risk marker
Carrying one copy of the G allele at this position has been identified in research as a marker associated with prostate cancer risk stratification. Because this is a complex trait influenced by many genetic and environmental factors, this result does not predict a specific health outcome. Please consult with your healthcare provider to discuss appropriate screening based on your personal and family medical history.
This genotype is found at varying frequencies across different ancestral groups, appearing as a common variant in many populations.
Potential risk marker
Carrying two copies of the G allele at this position is associated with prostate cancer risk stratification in some research studies. This finding is a statistical association rather than a direct cause of disease, and its clinical significance remains a subject of ongoing study. You should continue to follow standard medical guidelines for prostate cancer screening and discuss this result with your doctor.
This genotype is less common than the AA or AG genotypes in most populations, though it remains a recognized common variant.
What is rs16860513?
The rs16860513 variant is a single nucleotide polymorphism (SNP) located within the ITGA6 gene. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. This specific variant is classified as intronic, meaning it resides within an intron—a non-coding region of the gene that is removed during the process of creating a functional protein. While intronic variants do not change the protein sequence directly, they can influence how genes are regulated, expressed, or spliced. Researchers study these markers to understand how subtle variations in our genetic code might contribute to complex health traits, such as susceptibility to certain diseases or how the body responds to environmental factors.
The Role of the ITGA6 Gene
The ITGA6 gene provides the instructions for creating the alpha-6 subunit of integrin proteins. Integrins are essential molecules that act as bridges between the interior of a cell and the extracellular matrix, which is the structural framework surrounding cells. By facilitating cell adhesion and signaling, these proteins help cells communicate with their environment, influencing processes like tissue formation, cell migration, and structural integrity. In the context of cancer research, ITGA6 has been studied for its role in tumor progression and metastasis. Because integrins are involved in how cancer cells attach to tissues and move, variations in the expression or regulation of ITGA6 are of significant interest to scientists investigating how tumors grow and spread in various organs, including the prostate.
Research and Evidence Strength
The association between rs16860513 and prostate cancer is categorized as having moderate evidence strength. Large-scale genome-wide association studies (GWAS) have identified this variant as a marker that may help in the risk stratification of prostate cancer. It is important to note that while statistical associations have been observed, these findings do not imply a direct cause-and-effect relationship. Genetic risk is complex and typically involves the interplay of many different variants, environmental factors, and lifestyle choices. Current research continues to explore how this specific marker influences gene expression in both normal and tumor prostate tissues. Because the evidence is based on population-level statistics, it is not a diagnostic tool for individuals, and its clinical utility remains a subject of ongoing scientific investigation.
Population Frequency
The rs16860513 variant is considered a common genetic marker. Its frequency can vary across different ancestral populations, which is a standard observation in human genetics. Understanding these frequency differences is crucial for researchers to ensure that genetic studies are representative and that findings are applicable across diverse groups. Because it is common, many individuals carry one or more copies of this variant without necessarily developing the associated health conditions. Genetic databases continue to collect data to refine our understanding of how common this variant is globally.
Navigating Genetic Information
If you have received information about your status for rs16860513, it is important to view it in the proper context. This variant is a marker for research purposes and is not a clinical diagnostic test for prostate cancer. You cannot use this information to predict your personal health outcomes or to make medical decisions. Genetic markers are only one piece of a much larger puzzle that includes family history, age, and clinical screenings. If you are concerned about prostate cancer risk, the most effective approach is to consult with a healthcare professional. They can provide personalized guidance based on your complete medical history and current clinical guidelines, rather than relying on a single genetic variant.
How common is this variant?
The rs16860513 variant is documented as a common SNP across various global populations, with its specific allele frequencies varying by ancestry.
Frequently asked questions
Does having this variant mean I will get prostate cancer?
No. Having a specific genotype for rs16860513 does not mean you will develop prostate cancer. It is simply a marker that has shown a statistical association with risk in large population studies, not a diagnostic test.
Should I get tested for this variant?
Genetic testing for this variant is not currently recommended for routine clinical screening. If you have concerns about your prostate cancer risk, you should discuss appropriate screening options, such as PSA tests or physical exams, with your doctor.
Can I change my risk if I have this variant?
Genetic variants are inherited and cannot be changed. However, you can manage your overall health through lifestyle choices and regular medical check-ups as recommended by your healthcare provider.
Where can I find more information on ITGA6?
You can find reliable information about the ITGA6 gene and its functions on resources like MedlinePlus Genetics or the NCBI Gene database. These sites provide detailed, peer-reviewed summaries of gene functions and their roles in human health.
Sources & further reading
Educational information only, last refreshed 10/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16860513?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29